Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Patients with either histological confirmation or clinical diagnosis who are candidate for
orthotopic liver transplant(OLT) will receive Sorafenib 400mg 2 x day (BID) as a neoadjuvant
(bridging) treatment until transplant. If patient progresses or falls outside of the Milan
criteria on sorafenib patient can be treated per physician's discretion using local therapy.
Patient will be followed until 30 days after the orthotopic liver transplant (OLT).